Logo

radiopharmaceuticals

Sanofi Inks €100M Radiopharmaceutical Deal With RadioMedix, Orano Med

Sanofi will gain exclusive rights to commercialize the lead-212-based radiopharmaceutical AlphaMedix in somatostatin-expressing neuroendocrine cancers. 

In Brief This Week: Obsidian, Skyline, Mainz Biomed, Novartis, Synthekine, Vivet, Abdera

News items for the week of Sept. 2, 2024.

In Brief This Week: BioNexus Gene Lab, AC Immune, Nuvectis Pharma

News items for the week of Aug. 26, 2024.

Telix Seeks Approval of PET Imaging Agent Pixclara to Track Brain Cancer Treatment

Pixclara has potential as a companion diagnostic for Telix's LAT1-targeted radiopharmaceutical agent TLX101 in glioblastoma.

FDA Allowing Compassionate Use Access to Telix's Glioma PET Imaging Agent

Telix will seek FDA approval to sell TLX101-CDx as an imaging agent for advanced glioma patients. 

Jul 24, 2024

Telix Files for FDA Approval for New PSMA-PET Imaging Agent TLX007-CDx

Jul 18, 2024

Novartis Pivots to Aggressive Pluvicto Expansion Strategy as Growth Steadies in Q2
Premium

Jul 17, 2024

Full-Life Technologies, SK Biopharmaceuticals Ink Radiopharmaceutical Licensing Deal

Jun 6, 2024

ITM Lands €188M Equity Investment

May 23, 2024

Nuclidium, Guerbet Ink Deal to Develop Targeted Copper-Based Radiopharmaceuticals

May 16, 2024

Bayer Begins Phase I Trial of PSMA-Targeted Radionuclide Therapy in Prostate Cancer

May 10, 2024

In Brief This Week: Northwell Health Cancer Institute, Labcorp, AstraZeneca, Cellectis, Artbio

May 8, 2024

Blue Earth Diagnostics Sharing Posluma Data With Siemens Healthineers to Improve AI Tools

Apr 29, 2024

INmune Bio Starts Evaluating NK-Based Cell Therapy in Second mCRPC Cohort

Apr 23, 2024

Novartis Reports 10 Percent Sales Growth in Q1; Discusses Upcoming Regulatory Filings
Premium

Apr 23, 2024

FDA Approves Novartis' Lutathera for Children With Neuroendocrine Cancers

Mar 19, 2024

AstraZeneca Acquiring Fusion Pharmaceuticals in Deal Valued at $2.4B

Jan 31, 2024

Novartis' Pluvicto Sales Grew 53 Percent in Q4, Closing in on Blockbuster Status in 2023
Premium

Jan 24, 2024

Despite Frontline Benefit in Trial, GI Oncologists Want Better Way to Select Patients for Lutathera
Premium

Jan 19, 2024

In Brief This Week: Verastem, Atsena Therapeutics, Solid Biosciences, Perspective Therapeutics, More

Jan 18, 2024

Perspective Therapeutics Aiming to Raise up to $80.8 Million in Public Offering, Private Placement

Jan 17, 2024

Ratio Therapeutics Raises $50M in Series B Financing

Jan 9, 2024

Lantheus Holdings, Perspective Therapeutics Ink Multipart Radiopharmaceutical Deal

Dec 29, 2023

Best Precision Medicine Stories of 2023

Dec 27, 2023

Bristol Myers Squibb Acquires RayzeBio for $4.1B